Hyderabad: Amid a spike in Covid-19 cases and an acute shortage of Remdesivir, Hyderabad-based pharma major Dr Reddy’s Laboratories is not just ramping up production of the drug but has decided to slash the maximum retail price by half in the interest of patients.
The company said it will also be rolling out a liquid variant of Redyx, its Remdesivir brand, that will be faster to manufacture and supply.
“We are making every effort to ensure that Dr Reddy’s Remdesivir, sold under the brand name Redyx, reaches as many patients in India, as possible. We are ramping up production and are also bringing to market a liquid product that is faster to make and supply,” the company said.
“We have also reduced our MRP by 50% so that price is not a barrier to access, and a much larger number of patients can access it,” it added.
To ensure full visibility on the availability of the drug to patients and health professionals, the firm has set up a dedicated website that is updated in real-time to show city-wise availability of Redyx and Favipiravir at various stockists and hospitals across the country.
